<DOC>
	<DOCNO>NCT00148928</DOCNO>
	<brief_summary>Patients hormone-sensitive prostate cancer rise PSA , primary tumor treatment , treat P501-AS15 vaccine out-patients . The maximum dose 16 vaccination , give period approximately one year . Thereafter , patient ' long-term safety PSA status follow period approximately 11 month .</brief_summary>
	<brief_title>Safety &amp; Activity P501-AS15 Vaccine First-line Treatment Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA</brief_title>
	<detailed_description>This Phase I/II study conduct accord multicenter , open-label , single-group design approximately ten center Europe . At least 21 HSPC patient rise PSA primary tumor treatment enrol study . All patient treat out-patients receive treatment . The maximum dose 16 vaccination . Follow-up : The patient ' long-term safety PSA status follow period 48 week . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion criterion : Male , Aged 18 75 year , inclusive , Histologically cytologically proven adenocarcinoma prostate initiation therapy primary tumor , Radical prostatectomy progression disease rise PSA establish , Primary tumor present Gleason sum score â‰¤8 , Proven progressive hormonesensitive prostate cancer , Serum testosterone level 50 ng/dl , Free clinically evaluable metastatic disease ( rise PSA ) , ECOG Performance Status 0 1 , Normal organ function , Negative HBV antigen test , Negative HCV antibody test , The investigator believe patient comply requirement protocol , Written , inform consent obtain enrolment . Exclusion criterion : Orchiectomy , Received androgendeprivation therapy , include neo adjuvant androgendeprivation therapy , Any radiotherapy ( external beam radiotherapy and/or brachytherapy ) prostate cancer primary management , Receiving treatment continuous systemic anticancer medication , Received chronic administration immunosuppressant immunemodifying drug within six month first vaccine dose , Received investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , administration product plan study period , Receiving immunoglobulin and/or blood product receive product within three month precede first dose study vaccine plan receive product study period , Received commercial vaccine within week first study vaccination , Previous concomitant malignancy sit , except ( ) adequately treat nonmelanoma skin cancer , ( ii ) effectively treat malignancy remission &gt; 2 year consider investigator highly likely cure , Any clinical autoimmune disease ( except vitiligo ) , Family history congenital hereditary immunodeficiency , HIVpositive , Medical history include splenectomy irradiation spleen , History allergic disease reaction likely exacerbate component vaccine , Any known allergy hypersensitivity yeast yeast product , The patient present serious acute chronic illness ( e ) , e.g . active infection require antibiotic , bleeding/coagulation disorder , clinically significant heart disease ( NCIC CTG IIIIV ) , condition require concurrent medication allow study , Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule , History chronic alcohol consumption and/or drug abuse , Acute disease time enrolment . All vaccine administer person minor illness .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>